MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why ALDX Stock dropped -3.58% Today — RQD Quant Desk Flash
$0.66 -3.58% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.65
Aldeyra Therapeutics Inc. (ALDX) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $39.8M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.65 (-0.83%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALDX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (50/100 Composite)
🔍 WHY ALDX SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (26% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (24% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Cash Engine Quality6/20 pts (-14 pt drag)
Capital intensity & 0% operating margin leave 14 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$0.92-23.9% Next Q
58
Q2 (-2Q)Grade C$0.70-7.1% Next Q
55
Q3 (-1Q)Grade C-$0.65+1.5% Next Q
53
CurrentGrade D$0.66-1.4% Hist 90D α
50
Trajectory: C (58) → D (50)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ALDX Turnaround Squeeze
While ALDX currently carries a cautious 50/100 (D) rating due to Cash Engine Quality (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.15) and Max Pain ($0.69) forces dealer call-delta covering toward $6.23.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALDX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ALDX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ALDX Stock dropped -3.58% Today — RQD Quant Desk Flash
Aldeyra Therapeutics Inc. (ALDX) dropped -3.58% to $0.66, trading at 2% of its 52-week range ($0.55 – $5.93). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.55 – $5.93) with RSI-14 at 24.4 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.66 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ALDX Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALDX)
- ✓Walkthrough of ALDX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ALDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -56.58%▼ SUPPORT BREAKDOWN
2026-10-30O $0.67H $0.68L $0.55C $0.66VOL 896.6K
RES: $1.30SUP: $0.99SMA50: $1.15SMA200: $2.28
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ALDX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ALDX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ALDX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ALDX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALDX)
Health Care Rank #351 of 1016
⚔️ ATHE vs ALDX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ALDX vs. ATHE, GRDX, GRCE, SCYX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Aldeyra Therapeutics Inc. (ALDX) ranks #351 by composite RQD confidence (50/100, grade D) and #776 by equity capitalization ($39.8M). Within this direct 5-issuer industry benchmark cohort, ALDX leads on earnings valuation at N/A trailing P/E, while GRCE leads on capital efficiency and profitability with -18.9% ROIC and — gross margin. ATHE currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with ALDX at 50/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ALDX
ACTIVE
Aldeyra Therapeutics Inc. | D | 50/100 | — | — | -35.0% | -3.58% | $39.8M | Benchmark Subject |
| ATHE Alterity Therapeutics Limited | D+ | 58/100 | — | — | — | +2.93% | $40.7M | /athe-vs-aldx → |
| GRDX GridAI Technologies Corp. | E | 26/100 | — | -30.0% | -20.0% | -5.38% | $38.9M | /grdx-vs-aldx → |
| GRCE Grace Therapeutics Inc. | D- | 35/100 | — | — | -18.9% | -3.48% | $40.8M | /grce-vs-aldx → |
| SCYX SCYNEXIS Inc. | E | 34/100 | — | — | -35.0% | -2.28% | $38.4M | /scyx-vs-aldx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001341235In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aldeyra Therapeutics Inc. (ALDX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$33.8M, operating cash flow of -$33.3M, and free cash flow of -$33.3M (+22.8% YoY). On the balance sheet, ALDX closed FY2025 with $72.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$33.8M | -$33.3M | -$33.3M | $72.1M | $0 |
| FY2024 (FY) | 2024-12-31 | $0 | -$55.9M | -$43.2M | -$43.2M | $104.6M | $15.0M |
| FY2023 (FY) | 2023-12-31 | $0 | -$37.5M | -$30.3M | -$30.3M | — | — |
3. ALDX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ALDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Aldeyra Therapeutics Inc. (NASDAQ: ALDX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $0.66 (-3.58% 1D, market cap $39.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ALDX ranks #351 in composite RQD confidence.
How does ALDX compare to ATHE and GRDX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALDX carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ATHE (Alterity Therapeutics Limited) holds a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $40.7M) and GRDX (GridAI Technologies Corp.) posts a E grade (26/100 RQD, P/E N/A, ROIC -20.0%, cap $38.9M). Among the 5-stock peer group, ALDX leads on earnings multiple (N/A) while GRCE leads on capital efficiency (-18.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ALDX?
Per ALDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001341235), Aldeyra Therapeutics Inc. generated $0 in revenue, -$33.8M in net income, and -$33.3M in free cash flow against $72.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ALDX trading relative to its 50-day, 200-day, and 52-week technical levels?
ALDX last traded at $0.66 (-3.58% on volume of 418,108 shares), positioning the stock -42.61% below its 50-day simple moving average ($1.15) and -71.05% below its 200-day simple moving average ($2.28). Across its 52-week range of $0.55 to $5.93, ALDX sits at the 2.0% percentile with a 14-day RSI of 24.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.74).
ALDX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ALDX stock moving today?
Why ALDX Stock dropped -3.58% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.